WHITE PAPER
Precision Without Compromise:
How the Navigo™ 4D MRI Fusion Biopsy System Redefines the Standard for Prostate Fusion
MRI-US fusion biopsy is the standard of care for prostate cancer diagnosis for all men at risk, including biopsy-naive patients.¹ MP-MRI boasts a 93% sensitivity rate for clinically significant cancer detection, and has been clinically proven to be ideal for triage testing before a first biopsy.²
For urologists ready to shift fusion in-house, finding the right platform determines how well that transition impacts your patients and your practice’s bottom line.
With reimbursement for each additional MRI-targeted lesion, settling for a system that’s just “good enough” is leaving money on the table.
Download the white paper to learn why Navigo 4D Fusion is your best in-house MRI fusion solution.
Download the White Paper
A New Standard of Care and Profit Center
Delivering Unmatched Performance During Biopsy Procedures
Bringing fusion in-house is just the beginning. During procedures is where the true value of a fusion platform comes into view.
Systems that require manual intervention when patients shift result in workflow interruptions, missed registrations, incomplete biopsy maps, and compromised accuracy.
With Navigo, every step of the process is addressed with precision, from position to procedure to focal therapy planning and active surveillance, with a unique pricing model to make adoption within easy reach.
Real-time motion compensation
Fully-automated
biopsy marking
Biopsy preservation and advanced detection
Unique pay-performance model
Read Precision Without Compromise: How the Navigo™ 4D MRI Fusion Biopsy System Redefines the Standard for Prostate Fusion to learn more.
Sources​
-
Urol. 2020 Apr;203(4):706-712. American Urological Association Guidelines on mpMRI-guided biopsy.
-
Ahmed H, Bosaily A, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1